Allogene Therapeutics (ALLO)
NASDAQ:ALLO
Want to see ALLO full AI Analyst Report?
Allogene Therapeutics (ALLO) Ownership Overview
6.67% Insiders
8.68% Mutual Funds
23.39% Other Institutional Investors
9.46% ETFs
51.79% Public Companies and
Individual Investors
The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 41.53% of the company’s stock is owned by Institutional Investors, 6.67% is owned by Insiders, and 51.79% is owned by Public Companies and Individual Investors.
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
Mar 31, 2024 | xxxxxxxxxxxxx | $105564 | |
Mar 31, 2024 | xxxxxxxxxxxxx | $20446810 | |
Mar 31, 2024 | xxxxxxxxxxxxx | $8542630 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 13,432,017 | Institution | 3.89% | 26,058,113 | |
| 11,009,103 | Insider | 3.19% | 21,357,660 | |
| 8,379,840 | Institution | 2.43% | 16,256,890 | |
| 8,063,795 | Insider | 2.34% | 15,643,762 | |
| 7,438,545 | Institution | 2.16% | 14,430,777 | |
| 6,761,053 | Institution | 1.96% | 13,116,443 | |
| 6,207,969 | Institution | 1.80% | 12,043,460 | |
| 5,364,570 | Institution | 1.55% | 10,407,266 | |
| 3,830,998 | Institution | 1.11% | 7,432,136 | |
| 3,501,078 | Institution | 1.01% | 6,792,091 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 6,761,053 | Institution | 1.96% | 13,116,443 | |
| 5,364,570 | Institution | 1.55% | 10,407,266 | |
| 3,830,998 | Institution | 1.11% | 7,432,136 | |
| 2,745,270 | Institution | 0.80% | 5,325,824 | |
| 1,733,105 | Institution | 0.50% | 3,362,224 | |
| 1,724,476 | Institution | 0.50% | 3,345,483 | |
| 1,401,115 | Institution | 0.41% | 2,718,163 | |
| 1,208,862 | Institution | 0.35% | 2,345,192 | |
| 885,754 | Institution | 0.26% | 1,718,363 | |
| 600,290 | Institution | 0.17% | 1,164,563 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 8,427,791 | Institution | 2.44% | 18,288,306 | |
| 5,927,814 | Institution | 1.72% | 11,144,290 | |
| 3,724,564 | Institution | 1.08% | 7,225,654 | |
| 2,846,281 | Institution | 0.82% | 6,176,430 | |
| 1,695,818 | Institution | 0.49% | 3,289,887 | |
| 1,359,725 | Institution | 0.39% | 2,637,867 | |
| 1,345,171 | Institution | 0.39% | 2,555,825 | |
| 1,209,417 | Institution | 0.35% | 2,273,704 | |
| 994,379 | Institution | 0.29% | 1,889,320 | |
| 799,026 | Institution | 0.23% | 1,733,886 |
FAQ
Who Owns Allogene Therapeutics (ALLO)?
According to the latest TipRanks data, approximately 23.39% of the company's stock is held by institutional investors, 6.67% is held by insiders, and 51.79% is held by retail investors.
What percentage of Allogene Therapeutics (ALLO) stock is held by institutional investors?
According to the latest TipRanks data, approximately 23.39% of Allogene Therapeutics (ALLO) stock is held by institutional investors.
What percentage of Allogene Therapeutics (ALLO) stock is held by retail investors?
According to the latest TipRanks data, approximately 51.79% of Allogene Therapeutics (ALLO) stock is held by retail investors.
Who owns the most shares of Allogene Therapeutics (ALLO)?
Vanguard owns the most shares of Allogene Therapeutics (ALLO).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.